In8Bio INAB
NASDAQ INAB
$1.05 +0.06 (+6.06%)
At close: Oct 23, 2026 · 4:00 PM EDT

In8Bio (INAB) Other Non-Current Liabilities (2020)

Updated

In8Bio's Other Non-Current Liabilities came in at $17,000 for Q4 2020.

Analysis

In8Bio (INAB) Other Non-Current Liabilities (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 In8Bio 20.44 Mn -57.91 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 17,000.00
API Access

In8Bio Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=INAB&period=max&api_key=YOUR_API_KEY